{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:23:13Z","timestamp":1790677393893,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:00:00Z","timestamp":1537315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00415-018-9065-7","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T02:03:40Z","timestamp":1537322620000},"page":"2783-2788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry"],"prefix":"10.1007","volume":"265","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3925-5142","authenticated-orcid":false,"given":"Olivier","family":"Scheidegger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Leupold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Findling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai Michael","family":"R\u00f6sler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hundsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,19]]},"reference":[{"key":"9065_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ajmg.c.31317","volume":"160C","author":"N Raben","year":"2012","unstructured":"Raben N, Wong A, Ralston E, Myerowitz R (2012) Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am J Med Genet C Semin Med Genet 160C:13\u201321","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"9065_CR2","first-page":"45","volume":"26","author":"N Raben","year":"2007","unstructured":"Raben N, Roberts A, Plotz PH (2007) Role of autophagy in the pathogenesis of Pompe disease. Acta Myol Myopathies Cardiomyopath Off J Mediter Soc Myol 26:45\u201348","journal-title":"Acta Myol Myopathies Cardiomyopath Off J Mediter Soc Myol"},{"key":"9065_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","volume":"120","author":"J Chan","year":"2017","unstructured":"Chan J, Desai AK, Kazi ZB et al (2017) The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab 120:163\u2013172","journal-title":"Mol Genet Metab"},{"key":"9065_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","volume":"66","author":"PS Kishnani","year":"2009","unstructured":"Kishnani PS, Corzo D, Leslie ND et al (2009) Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 66:329\u2013335","journal-title":"Pediatr Res"},{"key":"9065_CR5","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","volume":"89","author":"E Kuperus","year":"2017","unstructured":"Kuperus E, Kruijshaar ME, Wens SCA et al (2017) Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study. Neurology 89:2365\u20132373","journal-title":"Neurology"},{"key":"9065_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M et al (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99\u2013109","journal-title":"Neurology"},{"key":"9065_CR7","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT Ploeg van der","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med 362:1396\u20131406","journal-title":"N Engl J Med"},{"key":"9065_CR8","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00415-013-6980-5","volume":"260","author":"T Hundsberger","year":"2013","unstructured":"Hundsberger T, Rohrbach M, Kern L, R\u00f6sler KM (2013) Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease. J Neurol 260:2279\u20132285","journal-title":"J Neurol"},{"key":"9065_CR9","unstructured":"(2010) BGE 136 V 395 see \n                    https:\/\/www.bger.ch"},{"key":"9065_CR10","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1007\/s00415-014-7402-z","volume":"261","author":"T Hundsberger","year":"2014","unstructured":"Hundsberger T, R\u00f6sler KM, Findling O (2014) Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis. J Neurol 261:1684\u20131690","journal-title":"J Neurol"},{"key":"9065_CR11","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1161\/01.STR.19.12.1497","volume":"19","author":"R Bonita","year":"1988","unstructured":"Bonita R, Beaglehole R (1988) Recovery of motor function after stroke. Stroke 19:1497\u20131500","journal-title":"Stroke"},{"key":"9065_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","unstructured":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111\u2013117","journal-title":"Am J Respir Crit Care Med"},{"key":"9065_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2377-7-39","volume":"7","author":"PW Duncan","year":"2007","unstructured":"Duncan PW, Sullivan KJ, Behrman AL et al (2007) Protocol for the Locomotor Experience Applied Post-stroke (LEAPS) trial: a randomized controlled trial. BMC Neurol 7:39","journal-title":"BMC Neurol"},{"key":"9065_CR14","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121\u20131123","journal-title":"Arch Neurol"},{"key":"9065_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/mus.10045","volume":"25","author":"ISJ Merkies","year":"2002","unstructured":"Merkies ISJ, Schmitz PIM, Van Der Mech\u00e9 FGA et al (2002) Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve 25:370\u2013377","journal-title":"Muscle Nerve"},{"key":"9065_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","volume":"257","author":"S Strothotte","year":"2010","unstructured":"Strothotte S, Strigl-Pill N, Grunert B et al (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91\u201397","journal-title":"J Neurol"},{"key":"9065_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","volume":"35","author":"C Regnery","year":"2012","unstructured":"Regnery C, Kornblum C, Hanisch F et al (2012) 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis 35:837\u2013845","journal-title":"J Inherit Metab Dis"},{"key":"9065_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1750-1172-7-73","volume":"7","author":"JM Vries de","year":"2012","unstructured":"de Vries JM, van der Beek NAME, Hop WCJ et al (2012) Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 7:73","journal-title":"Orphanet J Rare Dis"},{"key":"9065_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","volume":"33","author":"B Bembi","year":"2010","unstructured":"Bembi B, Pisa FE, Confalonieri M et al (2010) Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis 33:727\u2013735","journal-title":"J Inherit Metab Dis"},{"key":"9065_CR20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","volume":"259","author":"C Angelini","year":"2012","unstructured":"Angelini C, Semplicini C, Ravaglia S et al (2012) Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 259:952\u2013958","journal-title":"J Neurol"},{"key":"9065_CR21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser B, Stewart A, Kanters S et al (2017) Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol 264:621\u2013630","journal-title":"J Neurol"},{"key":"9065_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/mus.23658","volume":"47","author":"D-S Lin","year":"2013","unstructured":"Lin D-S, Chiang M-F, Ho C-S et al (2013) Low-frequency enzyme replacement therapy in late-onset Pompe disease. Muscle Nerve 47:612\u2013613","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-9065-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9065-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9065-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T19:07:53Z","timestamp":1568833673000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-9065-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,19]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["9065"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-9065-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,19]]},"assertion":[{"value":"27 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TH and KMR served as consultants, received funding for travel expenses and received honoraria from serving on a scientific advisory board from Genzyme, Switzerland. OF received travel expenses and honoraria from serving on a scientific advisory board from Genzyme, Switzerland. OS and DL received funding for travel expenses from Genzyme, Switzerland. RS declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The local ethics committee approved this retrospective analysis, and written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical standards"}}]}}